Australia markets closed

ABBV Jun 2024 230.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.04000.0000 (0.00%)
As of 11:26AM EST. Market open.
Full screen
Previous close0.0400
Open0.0200
Bid0.0000
Ask0.0000
Strike230.00
Expiry date2024-06-21
Day's range0.0400 - 0.0400
Contract rangeN/A
Volume4
Open interestN/A
  • Reuters

    UPDATE 1-AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports

    AbbVie is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter. AbbVie did not immediately respond to Reuters' request for a comment. In December, AbbVie announced back-to-back acquisitions - a $8.7 billion plan to buy Cerevel and its $10.1 billion deal for ImmunoGen, which was recently completed.

  • Bloomberg

    AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A

    (Bloomberg) -- Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.Most Read from BloombergNvidia Surges After Company Proclaims AI Has Hit 'Tipping Point'Biden Touts $1.2 Billion in Student Loan Relief With Eye to 2024Tech Up in Late Hours on Nvidia’s Bullish Outlook: Markets WrapChina Tightens Grip on Stocks With Net Sa

  • Zacks

    AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.